Literature DB >> 12458668

An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia.

P Veng-Pedersen1, S Chapel, R L Schmidt, N H Al-Huniti, R T Cook, J A Widness.   

Abstract

PURPOSE: To determine by pharmacodynamic (PD) analysis physiologically relevant parameters of the cellular kinetics of erythropoiesis in acute anemia.
METHODS: The PD relationships among erythropoietin (EPO), reticulocyte, and RBC (Hb) responses were investigated in young adult sheep in acute anemia induced twice by two controlled phlebotomies separated by a 4-week recovery period.
RESULTS: The phlebotomies resulted in rapid increases in plasma EPO, with maximal levels occurring at 3 to 8 days, followed by a reticulocyte response with a delay of 0.5 to 1.5 days. The Hb returned to prephlebotomy base line at the end of the 4-week recovery period. The EPO, reticulocyte count, and Hb responses were well described by a PK/PD model (r = 0.975) with the following cellular kinetics parameters: the lag time between EPO activation of erythroid progenitor cells and reticulocyte formation; the reticulocyte-to-RBC maturation time; the reticulocyte and Hb formation efficacy coefficients, quantifying EPO's efficacy in stimulating the formation of reticulocytes and Hb, respectively; the C50 PK/PD transduction parameter defined as the EPO level resulting in half the maximum rate of erythropoiesis.
CONCLUSION: Physiologically relevant cellular kinetics parameters can be obtained by an endogenous PK/PD analysis of phlebotomy data and are useful for elucidating the pathophysiologic etiology of various anemias.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458668     DOI: 10.1023/a:1020797110836

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  18 in total

1.  Basic pharmacodynamic models for agents that alter production of natural cells.

Authors:  W Krzyzanski; R Ramakrishnan; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

2.  A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep.

Authors:  S H Chapel; P Veng-Pedersen; R L Schmidt; J A Widness
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

3.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

4.  Analysis of erythropoiesis by erythroid colony formation in culture.

Authors:  J W Adamson; B Torok-Storb; N Lin
Journal:  Blood Cells       Date:  1978

Review 5.  Kinetics of the formed elements of human blood.

Authors:  C A Finch; L A Harker; J D Cook
Journal:  Blood       Date:  1977-10       Impact factor: 22.113

6.  Effect of chronic erythropoietin administration on plasma iron in newborn lambs.

Authors:  C Peters; M K Georgieff; P A de Alarcon; R T Cook; L F Burmeister; L S Lowe; J A Widness
Journal:  Biol Neonate       Date:  1996

7.  Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.

Authors:  J S Kaufman; D J Reda; C L Fye; D S Goldfarb; W G Henderson; J G Kleinman; C A Vaamonde
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

Review 8.  Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications.

Authors:  A Markham; H M Bryson
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

9.  A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies.

Authors:  J A Widness; R L Schmidt; P Veng-Pedersen; N B Modi; S T Sawyer
Journal:  J Lab Clin Med       Date:  1992-03

10.  The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.

Authors:  T Salmonson; B G Danielson; B Wikström
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

View more
  14 in total

1.  Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.

Authors:  Wojciech Krzyzanski; Sukyung Woo; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-25       Impact factor: 2.745

2.  Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-13       Impact factor: 2.745

3.  A 'bottom-up' approach for endo-PK/PD analysis.

Authors:  S Neelakantan; J A Widness; R L Schmidt; P Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2006-10       Impact factor: 1.627

4.  Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis.

Authors:  Nidal H Al-Huniti; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.

Authors:  Matthew Rosebraugh; John A Widness; Peter Veng-Pedersen
Journal:  Drug Metab Dispos       Date:  2011-04-01       Impact factor: 3.922

6.  Increased erythropoietin elimination in fetal sheep following chronic phlebotomy.

Authors:  Kevin J Freise; John A Widness; Jeffrey L Segar; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pharm Res       Date:  2007-04-25       Impact factor: 4.200

7.  Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys.

Authors:  Rune V Overgaard; Mats Karlsson; Steen H Ingwersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-22       Impact factor: 2.745

8.  Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep.

Authors:  Kevin J Freise; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-22       Impact factor: 2.745

9.  Hypoxic stress tolerance of the blind subterranean mole rat: expression of erythropoietin and hypoxia-inducible factor 1 alpha.

Authors:  Imad Shams; Aaron Avivi; Eviatar Nevo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

10.  Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep.

Authors:  Kevin J Freise; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-14       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.